Showing posts with label existing HPV infection. Show all posts
Showing posts with label existing HPV infection. Show all posts

Tuesday, August 23, 2011

Gardasil’s Adverse Effects: The Institue of Medicine Reports

Share


On Thursday August 25 at 1:00 PM the Institute of Medicine’s Ellen Wright Clayton (Chair of the committee) plus S. Claiborne Johnston and Douglas Barrett (members of the committee) will host an audio webcast to discuss the committee’s new report, Adverse Effects of Vaccines: Evidence and Causality . The report will be released at 11 AM on August 25 and can then be downloaded at www.iom.edu/vaccineadverseeffects.

The report is not just about Gardasil—it’s about all vaccines covered by the Vaccine Injury Compensation Program, including the chickenpox, flu, Hepatitis A and B, meningococcal, tetanus, MMR, pertussis, diphtheria, tetanus, etc. It will review the “epidemiological, clinical, and biological evidence regarding adverse health events associated with specific vaccines…the committee will author a consensus report with conclusions on the evidence bearing on causality and the evidence regarding the biological mechanisms that underlie specific theories for how a specific vaccine is related to a specific adverse event.”

Want to take part?

Email your comment to vaccinesafety@nas.edu, but bear in mind that any comment and identifying info you give, including your name, email address, and physical address, will be included in the Public Access File.

Register to take part in the audio webcast at www.nationalacademies.org; you’ll also find a link to the report there after 11 AM and will be able to email questions to the committee during the webcast via a link.

Download the report at 11 AM and make a note of any questions you might have. Should be interesting.





Thursday, July 21, 2011

Would you choose Gardasil or circumcision against HPV?

Share
I know that guys who haven’t been snipped hate to hear this, but a new study in South Africa might make you want to revisit the subject of circumcision in terms of HIV, HPV, genital warts, etc. (and make women check out prospective partners a little more closely). The study shows that circumcision reduces the risk of contracting HIV by 76 percent.

76 percent. WOW. And of course, if you don’t get HIV, you’re not going to pass it along to your partner(s), either.

While it’s hard to say whether those statistics would hold up in the US, where life, health and risks are different, it’s hard to imagine that circumcision could make less than a very worthwhile difference in transmission rates. And it’s not just a matter of cleanliness. The cells in the foreskin are particularly vulnerable to viruses.

Oh, and then there’s the nasty subject of genital warts. Circumcision cuts (sorry) that chance by 28-34 percent, too, according to another randomized trial in Africa.

HPV? Not so much. One study found a 27.9% prevalence of high-risk HPV genotypes in uncircumcised males and only an 18.0% prevalence in circumcised males. Their female partners’ risk was 38.7% (uncircumcised partner) and 27.8% (circumcised partner) and it is, of course, impossible to know which way the infection went. But that’s still significant, either as an adjunct to the HPV vaccine series—whether Gardasil or Cervarix—or as part of a well-thought out strategy to lower risk.

As reported by Michael Smith for MedPage Today: “The procedure offers limited protection against most high-risk types, (researchers) noted, while the HPV vaccine is highly effective, but only against a limited number of genotypes. "The two interventions are likely to have important synergistic effects," they concluded.

The odd thing is that Medicaid, which serves some of our most vulnerable populations, doesn’t pay for circumcision in 16 states, and yet the US is currently paying for males to get circumcised in Swaziland to the total tune of $30 million. Talk about “things that make you go hmmmmmmm…”

The current pro-Gardasil campaign has perhaps made many people lose sight of the fact that there’s a heck of a lot worse things out there than HPV. With rates of women getting their annual check-ups already dropping in Australia, where Gardasil has been provided free by the national health system, it’s clear that the vaccine carries a subconscious feeling of… phew, I’m safe from STDs.

You’re not. Whether you choose Gardasil or not, just remember that a multi-pronged (sorry again) approach to sexual health is crucial. Keep your immune system healthy (get enough sleep and enough veggies and fruits, quit smoking etc.), use condoms (which will help against HPV and HIV but won't eliminate the risk, particularly for HPV), and apply the infamous Seinfeld “sponge-worthy” criteria to potential partners (is he/she really worth it?).

And guys, it’s up to you. If you’re not circumcised, think about it for your sake and your partner’s sake. Would you do it? If not, why not?

Wednesday, August 25, 2010

Worrisome Gardasil side effect: cervical cancer screening rates drop significantly

Share
The number of young women getting regular Pap tests has dropped quite significantly in Australia, where Merck’s Gardasil vaccine has been administered to almost all girls aged 12-13 via a school-based program. Women up to the age of 26 have also been able to receive the three-shot HPV vaccine free of charge through a now-ended catch-up program.

Health authorities are concerned about the ten percent drop in screenings among 25-29 year olds. The problem, they believe, may be that young women have been “lulled into a false sense of security” by Gardasil, which is advertised as a vaccine against cervical cancer.

Merck’s human papillomavirus vaccine actually only protects against the two HPV strains that cause 65-70 percent of cervical cancer, so it’s essential that women continue to get regular screenings. It’s particularly important because replacement disease, whereby other strains of the virus fill the biological niche left by the two vaccine-relevant strains, may well become an issue. And so far, although the vaccine has proved very effective against the vaccine-relevant strains, overall cervical abnormality rates have dropped by only  17-45 percent.

Regular Pap smears alone can eliminate at least 90 percent of cervical cancers. When a woman gets an HPV test along with the smear, there’s very little chance that cervical cancer will sneak up on  her. (See here .) Women are advised to go for screenings every 1-3 years; screenings are also important because doctors will usually check for breast cancer and other health issues at the same time.

All in all, it’s hardly surprising that Australian health officials are "concerned."  And if you or your daughter have had the Gardasil shots and have shelved regular exams, well, don't, is all I can say.

© 2010 www.gardasilhpv.com


Permission is freely given to accurately reproduce the first five paragraphs of this article, along with a link back to this site and the entirety of the article.

Thursday, February 25, 2010

Merck funding and the push to give Gardasil without parents’ knowledge or consent

Share
Well, color me naïve. Last week I wrote here about two ill-advised bills currently attempting to make it legal for clinics and school nurses to give children HPV shots (Merck’s Gardasil is the brand most commonly used in the US)—regardless of age, and without their parents knowing a thing about it.

"Although some bloggers have speculated about the motives of these zealous legislators, particularly with regards to campaign contributions by Merck,” I wrote, “I don’t doubt that they think they’re doing the right thing—even if they’re in fact being preposterously over-reaching.”

Now a regular reader has written to let me know that Senator Liz Krueger is in fact a member of Women in Government, a group that was heavily criticized for attempting to make vaccination with Gardasil mandatory for public school attendance after receiving substantial funding from Merck.

OK, sometimes I’m a real innocent.

Thursday, February 18, 2010

Gardasil pros and cons

Share
Gardasil has been hailed as the first vaccine against cancer, protecting women against some of the strains of human papillomavirus. HPV can, in a tiny percentage of cases, cause cervical cancer. Gardasil also been reviled as oversold and potentially dangerous. Here’s what you need to know:

• Up to 80 percent of people will get HPV, a virus akin to the common cold, in their lifetime. There are more than 100 strains of HPV, multiple strains of which COULD cause cancer in limited circumstances.

• 95 percent of those infections are self-limiting—they’ll be beaten off by your immune system, leaving you immune to further infection with the same strain.

• Only if an infection becomes persistent could it cause pre-cancerous lesions.

• Your behavior dramatically affects the chances of an infection becoming persistent.

• If you smoke, you have up to a 2,700 percent greater chance of getting a persistent HPV infection. (Anthony Gunnell, M.A.Sc., Karolinska Institutet, Stockholm; November 2006, Cancer Epidemiology, Biomarkers & Prevention)

• If you don’t eat vegetables and fruit regularly, you are 50 percent more likely to get a persistent HPV infection. (Rebecca L. Sedjo, MSPH, et al: University of Arizona, US; Cancer Epidemiology, Biomarkers & Prevention)

• If you have multiple sexual partners, you will exponentially increase your chances of getting a persistent HPV infection.

• Oral birth control and having sex at a young age may increase HPV risks.

• Being uncircumcised or having an uncircumcised partner increases HPV risks.

• Insufficient sleep on a regular basis, drug use—anything, in fact, that depresses your immune system—will increase your chances of getting a persistent HPV infection.

• With all that, if you get regular Pap smears, the chances of an infection progressing to pre-cancerous lesions and then cervical cancer are very small, and if it does, it is extremely curable when caught early. About 4000 women, some 60 percent of whom have not had smear tests, will die of cervical cancer in the US this year. It is twice as likely to affect Hispanic women and 50 percent more likely to affect African American women, probably because of economic factors. The number of cases drops by about 4 percent annually.

Gardasil
• Gardasil protects against the two strains of HPV, 16 and 18, that currently cause close to 70 percent of cervical cancer, plus two wart-causing strains. There are more than 100 strains of HPV. Merck’s research shows a small degree of cross-protection against strains not covered by the vaccine.

• Gardasil is a novel type of genetically engineered vaccine.

• Although ads imply that you will not get cervical cancer if you get Gardasil, Gardasil does not protect against many oncogenic strains of HPV. So far, Merck’s research has shown a rather meager 17-45 percent reduction in all cervical abnormalities in vaccinated girls. Recent figures of 89 percent reduction refer only to abnormalities and persistent infections caused by the four vaccine-type strains and do not include abnormalities caused by other strains.

• Although HPV16 and 18 caused the majority of invasive cervical cancer in a sample of women in New Mexico, the overall proportion attributable to HPV16 has dropped over 20 years, giving way to non-18 types. (C.M.Wheeler, PhD, University of New Mexico; Journal of the National Cancer Institute 2009).

• There is some concern that non-vaccine HPV types will fill the biological niche, an effect known as replacement disease. Merck does not think this likely, although it has happened with the vaccine Prevnar.

• The effect on natural immunity and duration of protection is currently unknown. Nor is the effect of new HPV infection in older adults when immunity has worn off.

• Merck’s research showed initially that Gardasil caused a 44.6 percent increase in the highest grade of pre-cancerous lesions in women who were already infected with vaccine-type HPV. Merck determined that the study was unbalanced and that those women also had high risk factors such as smoking. After ‘balancing’ the study, the combined figure for subgroup studies showed an enhanced risk of disease of 11.7 percent for females who had vaccine-type HPV at the start of the study.

• If you are already sexually active, get an HPV test prior to vaccination, particularly if you smoke or are otherwise high-risk.

• A neurologist has expressed concern about unusual immune response-mediated inflammation in the spine of a girl who died from an unusually rapid onset ALS-type disease and believes it may be associated with Gardasil.

• The FDA associates Gardasil with heightened risks of syncope and blood clots.

• Gardasil has also been associated anecdotally with Graves Disease, paralysis, Guillaine-Barré syndrome, seizures, chronic headache, and various autoimmune diseases although not at statistically extraordinary levels. Merck’s studies showed a slightly elevated risk of various types of arthritis. Incidence of autoimmune disease, which is triggered in susceptible people by environmental factors, is rising rapidly and an ever-increasing lifetime burden of vaccines and accompanying adjuvants may be a factor. This has not been proven, however. In trials of Gardasil, placebo vaccinations used an aluminum-containing adjuvant, something that could mask sideeffects.

• You should still get regular Pap tests, even if you have been inoculated with Gardasil.

It’s important to honestly assess your family medical history and lifestyle prior to getting the course of vaccinations. Read up on the facts. Gardasil may well be right for you, but it is not 100 percent effective or safe. Know its limitations—and yours.

Wednesday, October 21, 2009

Gardasil Optional, Not Recommended, for Boys--Will You Pay for It?

Share
It’s up to you now. The Advisory Committee on Immunization Practices voted almost unanimously to tell doctors that they’re free to give boys the Gardasil vaccine as a way of avoiding future bouts with genital warts—which affect about one percent of the population—but they’re not going to recommend it as a routine vaccination.

Nor do they plan to recommend it as an “anti-cancer” vaccine, which is the way it’s been sold to many millions of girls. Although the HPV virus can cause esophageal, anal, testicular, penile and perineal cancer in boys, such cancers are very rare, and even then a large percentage aren’t associated with the human papillomavirus. The only real advantage would be to protect future partners.

Merck, with billions on the line, had determined that the vaccine would be very cost-effective for boys by assuming that the vaccine would be 100 percent effective in preventing cancer and that the vaccine would cost $400 per child—at $360 for the cost of the shots alone, that doesn’t leave much to pay the cost of three visits to the doctor.

A Harvard study, however, went on the assumption that the vaccine would be 75 percent effective and cost $500 per child, and found that the cost of vaccinating boys would be spectacularly cost-ineffective.

The Advisory Committee apparently agreed with Harvard.
There is certainly no reason to assume that Gardasil will be 100 percent effective. Merck’s own study of more than 4,000 boys didn’t even find that, and Gardasil trials have shown the HPV vaccine to be just 17-45 percent effective in preventing cervical abnormalities in girls thus far. Gardasil has also been associated anecdotally with a number of rare, but serious, side effects, including autoimmune diseases and a form of ALS.

Meanwhile, it’s doubtful that many insurance companies will now pay for Gardasil for boys, although government programs may do so for those on Medicaid. Parents might prefer to be sure that their children understand the importance of getting annual exams as adults and of eating fruits and vegetables, avoiding smoking, being circumcised, getting sufficient sleep, and limiting the number of sexual partners—all factors that are known to substantially cut the risk of getting a persistent HPV infection.

So are you willing to fork over the cash yourself? Do you think Gardasil’s worth it?

Sunday, October 18, 2009

Is There a Gardasil / ALS Connection?

Share
All it would take is for neurologists to ask young female patients—and soon, young men too—a simple question.

“You have symptoms of ALS. Did you have the Gardasil vaccination?”

That’s the only way that we’re going to eventually find out whether the unusually rapid-onset ALS-like paralysis that killed Jenny Tetlock and Whitney Baird was indeed related to their recent vaccinations with Gardasil.

Up until now, no-one’s been asking. Most parents take routine vaccinations for granted and don’t think to bring it up. Merck and the FDA insist there’s no link. But at the 134th meeting of the American Neurological Association, Catherine Lomen-Hoerth, MD, director of the ALS Center at University of California San Francisco Medical Center, was asking.

Jenny Tetlock died from a neurological disease, mediated by immune responses, which led to extensive damage in her spinal cord. Lomen-Hoerth noted the unusual inflammation in Jenny’s spine and announced that she and her team are planning to study girls with ALS, both those who got the vaccination and those who didn’t, to compare symptoms and pathological features.

Hopefully, neurologists will now start asking about Gardasil—so simple!—and perhaps even comb through the records of any current and deceased patients with juvenile ALS, and then send the information on to Lomen-Hoerth.  It won't just be Jenny's parents who are saying, look, maybe there's no connection, but we want to know for sure.

And it’s not at all irrational to ask that question. Right now, there’s no causal link established between Gardasil and ALS, and two cases among millions of girls safely inoculated with the HPV vaccine means zip. However, given the unusual spinal inflammation (not a hallmark of ALS) and Jenny and Whitney’s shared history of a childhood autoimmune skin disorder that might have made them more vulnerable; given that periods of paralysis have marked mystery post-Gardasil medical conditions in a number of girls—given all that, there’s good reason to ask the question seriously.

Tuesday, August 25, 2009

Gardasil — Exempt from Truth in Advertising Standards?

Share
People who ask questions about Gardasil are invariably told that they’re scientific ignoramuses, endangering their children with their crazy paranoia. Last week, however, JAMA, the Journal of the American Medical Association, issued stinging critiques of the over-selling of the HPV vaccine and the potential skewing of any risk/benefits analysis. It was rare criticism from the medical profession.

The truth is, we have more legal protection from an under-powered blender than we do from a vaccine.

Gardasil could well be the best thing since the invention of SmartPhones. But it could also alter our life for the worse, permanently, or it could simply be a waste of time and money. Merck and the FDA are making highly educated guesses, but you’d never know that from the hype. As consumers, isn’t it time we started demanding a little respect and honesty? Don’t we deserve sufficient information to come to a reasonable decision?

Under the Federal Trade Commission Act, advertising must be truthful and fair, and it must not deceive. Advertisers must have evidence to back up their claims. An ad is considered deceptive if it either contains a statement or omits information that might well mislead consumers who are acting reasonably under the circumstances. It also must not omit information that is important to a consumer’s decision to use or buy the product.

With Gardasil’s unprecedented marketing, said Drs. Sheila and David Rothman in JAMA, “by making the vaccine’s target disease cervical cancer, the sexual transmission of HPV was minimized, the threat of cervical cancer to adolescents was maximized, and the sub-populations most at risk practically ignored…the material [put out by Merck-funded PMAs] did not address the full complexity of the issues surrounding the vaccine and did not provide balanced recommendations on the risks and benefits.”

Science can be defined as ‘what we know so far.’ Or as Dr. Charlotte Haug put it in her JAMA editorial about Gardasil, “medical knowledge is typically incomplete and ambiguous.” Often, what we think we know turns out to be wrong, or just the tip of the iceberg. It would be totally irrational to reject all medical science on the basis that we might find out something to the contrary later, but it is equally irrational to try to make a decision about a new treatment without being in possession of all the known facts, particularly when huge financial benefits to the vendor weigh in.

“GARDASIL is the only cervical cancer vaccine that helps protect against 4 types of human papillomavirus (HPV): 2 types that cause 70% of cervical cancer cases, and 2 more types that cause 90% of genital warts cases,” says Merck. “Be one less,” say the ads. The implication: if you don’t get Gardasil, you do get cervical cancer.

Here’s my Truth in Advertising version.

Gardasil targets the two strains of the HPV virus that currently cause 70 percent of cases of cervical cancer and two strains that cause genital warts. Your chance of dying from cervical cancer is extremely small if you have regular check-ups. HPV may also cause (even more rarely) cases of oral cancer, anal cancer, and penile cancer. We do not yet know whether Gardasil will be effective against these cancers and will not know for several decades, but the hypothesis seems likely to some degree.

You can reduce your small chance of developing HPV-related cancers dramatically by eating healthy foods, by not smoking, by limiting your sexual partners, and by undergoing regular screenings. 95 percent of cases of HPV are currently shrugged off by the body. You should consider your lifestyle honestly when making a risk/benefit analysis.

Gardasil may offer some further protection. After 3.6 years, the results from two randomized, placebo-controlled trials following 17,622 women who were vaccinated with Gardasil after showing no previous exposure to 14 HPV types and had normal Pap smears to begin with were:

· 17 to 22 percent reduction in ASC-US: atypical squamous cells of undetermined significanceassociated with a high-risk type of HPV

· 17 percent reduction in LSIL: low-grade squamous intraepithelial lesion

· 36 percent reduction in ASC-H: atypical squamous cells/cannot exclude high-grade squamous intraepithelial lesion

· 45 percent reduction in HSIL: high-grade squamous intraepithelial lesion

Colposcopies were reduced by 20 percent, cervical biopsies by 22 percent and surgery and other invasive treatments by 42 percent.

Protection against genital warts appears to be extremely good.

We do not know whether replacement diseases will occur should non-vaccine strains of the virus (there are more than 100, and at least 15 are known to be oncogenic) fill the biological niche left by vaccine strains. We do not believe that this is likely but the vaccine Prevnar has shown that it can happen.

We do not know how Gardasil will affect natural immunity to the more than 100 strains of HPV.

We do not know how long immunity will last and whether single, or perhaps multiple, booster shots will be necessary. We do not know whether, should immunity to HPV-16 and HPV-18 wear off, older adults will be able to fight off the virus as well as younger adults.

Data from the passive VAERS system that is used to monitor vaccine adverse events, along with data from clinical trials, appears to indicate that Gardasil is well-tolerated by the vast majority of individuals. The FDA has determined a slightly greater risk of fainting and associated injury and of blood clots.

Anecdotal evidence and VAERS reports associate Gardasil with an increased risk of auto-immune disease and neurological problems, including rapid-onset ALS, arthritis, Graves Disease, paralysis, seizures, chronic headache, etc., predominantly in very active girls, but no causal link has been found at this time and incidence does not occur at a very significantly greater rate than in the general population. Incidence of auto-immune disease, which may be triggered in genetically pre-disposed individuals and more often in women by environmental factors, is generally rising. We do not know why. We do not know if a rapidly increasing lifetime burden of vaccine adjuvants plays some part, although high levels of aluminum have reportedly been found in spinal taps from some affected girls.

There was concern that initial studies of Gardasil showed a 44.6 percent increase in CIN 2/3 (the highest grade of pre-cancerous lesion) in a sub-group of individuals who had existing vaccine-type infections at time of vaccination. Further analysis showed that an unbalanced proportion of these subjects may have had enhanced risk factors such as a current smoking habit or a history of cervicovaginal infection or STD. Background evidence provided to the committee approving Gardasil concluded that, after balancing risk factors and sub-dividing sub-groups, vaccination could be said to reduce CIN2/3 by a modest 5.5 percent. Overall, a combined figure for subgroup studies showed an enhanced risk of disease of 11.7 percent in subjects who tested positive for vaccine-relevant HPV at the beginning of the study.

You may wish to get an HPV test and/or a pregnancy test prior to vaccination. You may wish discuss the advisability of vaccination with your doctor if you or your family has a history of autoimmune disorders.

You should not get Gardasil if you’re allergic to yeast or if you’re pregnant or planning to become pregnant soon.

You should report any and all potential adverse reactions to VAERS, being sure to include valid contact information, and not just all immediately post-vaccination allergic reactions, as the CDC’s handout implies.

Tuesday, August 4, 2009

Australia Approves Gardasil for Women Up to Age 45

Share
Australia’s Therapeutic Goods Administration (TGA), roughly the equivalent of the United States’ FDA, has approved the Gardasil vaccine for use by women up to age 45. Previously, it had been approved only for ages 9-26. The vaccine was developed by Professor Ian Frazer, who was named Australian of the Year in 2006.

Earlier this year the FDA refused to allow Gardasil to be used in older women, citing the need for completion of an ongoing 48-month study and an analysis of the data.

The FDA’s caution may well spring from background information provided for the Vaccines and Related Biological Products Advisory Committee (VRBPAC) back in May 2006. The Committee was extremely concerned about data that showed that when the vaccine is given to a woman with a dormant or harmless form of HPV, the virus can become activated, increasing the likelihood of precancerous lesions developing by a startling 44.6 percent. The vaccine does not clear existing infections.

The TGA’s decision was likely spurred by a recent Columbian study funded by Gardasil maker Merck. It found that the vaccine was 91 percent effective in preventing new infections in women aged 24-45 if—and this is a big 'if'—they had never previously had HPV or cervical disease. The Australian public health service will not provide the vaccine free of charge for women under or over the ages of 12-26 as it clearly is not cost-effective, recommending instead that women continue to be vigilant about getting regular Pap smears.

Gardasil protects against two cancer-causing strains and two genital-wart causing strains of human papillomavirus (HPV). There are thought to be more than 100 strains of HPV, about 40 of which can cause cancer, and about 80 percent of the population will be infected with it at some point in their life. Some 95 percent of infections are shrugged off by the body within about 18 months, leaving a natural immunity to that strain. Only persistent infections can cause the lesions that might eventually become cervical cancer. Most lesions are easily detected during an annual Pap smear test in developed nations, although cervical cancer is a major killer in some countries where women do not have access to routine health care.